Loading
Latest filing published 31 Jan 2023 for Nabriva Therapeutics plc, €193.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Steven P. Gelone in Nabriva Therapeutics plc, where the filings describe the role as chief executive. Between 23 June 2017 and 29 January 2023, the trades on record add up to 77 filings.
In open-market terms, that means 1 purchase worth €33k on one side and 2 sales worth €15k on the other. Purchases outweigh sales by €18k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 69 share grants and 4 option exercises.
On 31 January 2023 came the latest disclosure, a share grant for €193 in Nabriva Therapeutics plc. The latest purchase dates back some time: it was published 3,041 days ago, on 26 June 2018. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 43 declarations